PubRank

Gordon B Mills

Author PubWeight™ 636.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006 18.44
2 Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002 16.38
3 Integrated genomic characterization of endometrial carcinoma. Nature 2013 14.29
4 The somatic genomic landscape of glioblastoma. Cell 2013 11.73
5 Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005 11.46
6 The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013 11.29
7 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007 11.21
8 The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009 9.01
9 An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008 8.12
10 Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006 7.73
11 Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012 6.80
12 The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007 6.22
13 Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011 6.15
14 Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009 5.68
15 Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002 5.52
16 Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011 5.28
17 ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008 5.19
18 High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011 4.78
19 AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009 4.71
20 The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004 4.69
21 Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007 4.60
22 Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 2011 4.55
23 A module of negative feedback regulators defines growth factor signaling. Nat Genet 2007 4.35
24 Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008 4.25
25 Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005 4.18
26 Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006 4.13
27 Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013 3.85
28 Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 2007 3.84
29 Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005 3.80
30 Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009 3.59
31 Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 2010 3.53
32 Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010 3.53
33 An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2012 3.48
34 Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009 3.36
35 Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003 3.32
36 A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 2010 3.25
37 Non-parametric quantification of protein lysate arrays. Bioinformatics 2007 3.18
38 Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009 3.14
39 ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A 2010 3.03
40 A genetically defined model for human ovarian cancer. Cancer Res 2004 3.02
41 Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2015 3.00
42 Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005 2.98
43 Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 2005 2.96
44 Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004 2.96
45 Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013 2.94
46 Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 2007 2.94
47 Functional proteomic profiling of AML predicts response and survival. Blood 2008 2.90
48 Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007 2.89
49 HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003 2.84
50 PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2010 2.79
51 Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009 2.76
52 Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012 2.71
53 Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012 2.68
54 The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 2006 2.64
55 Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011 2.64
56 The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008 2.63
57 A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 2013 2.63
58 A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007 2.62
59 BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 2006 2.61
60 Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004 2.50
61 PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011 2.50
62 Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002 2.45
63 Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004 2.44
64 Modeling precision treatment of breast cancer. Genome Biol 2013 2.42
65 PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013 2.38
66 Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002 2.37
67 Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011 2.34
68 Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004 2.32
69 A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008 2.30
70 Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008 2.29
71 Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013 2.29
72 Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007 2.28
73 Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012 2.27
74 Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 2006 2.24
75 Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 2009 2.21
76 Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002 2.18
77 Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007 2.14
78 Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol Cell 2012 2.11
79 Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009 2.10
80 Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 2010 2.10
81 Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 2013 2.09
82 Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002 2.03
83 Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008 2.01
84 Uniparental disomy in cancer. Trends Mol Med 2009 1.99
85 Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 2003 1.97
86 Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003 1.95
87 Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010 1.95
88 Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007 1.94
89 Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2012 1.92
90 Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 2002 1.91
91 Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2003 1.91
92 Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell 2011 1.89
93 PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 2010 1.85
94 MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012 1.85
95 Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009 1.84
96 PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012 1.83
97 AMPK: a contextual oncogene or tumor suppressor? Cancer Res 2013 1.82
98 Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011 1.81
99 Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 2013 1.80
100 Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010 1.80
101 Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007 1.79
102 Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem 2009 1.78
103 Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 2011 1.78
104 Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 2012 1.77
105 Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 2012 1.76
106 ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011 1.76
107 Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003 1.75
108 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003 1.74
109 Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 2003 1.73
110 Emerging role of RAB GTPases in cancer and human disease. Cancer Res 2005 1.71
111 Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010 1.71
112 Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 2006 1.68
113 Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 2007 1.67
114 Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 2011 1.64
115 TCPA: a resource for cancer functional proteomics data. Nat Methods 2013 1.64
116 Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 2010 1.62
117 Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 2006 1.61
118 Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008 1.61
119 Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 2010 1.59
120 Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 2014 1.57
121 Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012 1.56
122 Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 2012 1.55
123 A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 2011 1.53
124 Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009 1.53
125 Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 2009 1.53
126 Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 2005 1.51
127 Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009 1.48
128 Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 2010 1.48
129 Mask is required for the activity of the Hippo pathway effector Yki/YAP. Curr Biol 2013 1.48
130 Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 2007 1.45
131 A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol 2008 1.45
132 G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood 2005 1.45
133 Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 2012 1.44
134 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 2009 1.43
135 Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009 1.43
136 CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010 1.42
137 Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A 2011 1.41
138 Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009 1.39
139 Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 2010 1.38
140 Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 2009 1.38
141 Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 2013 1.36
142 Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 2002 1.36
143 A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci U S A 2006 1.36
144 Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 2008 1.34
145 Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 2009 1.33
146 Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 2012 1.32
147 Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 2011 1.32
148 Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 2010 1.31
149 Assessing BRCA carrier probabilities in extended families. J Clin Oncol 2006 1.30
150 Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007 1.29
151 High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2009 1.29
152 HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 2011 1.28
153 Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One 2012 1.28
154 Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010 1.28
155 cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 2012 1.28
156 Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther 2009 1.28
157 ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 2009 1.27
158 The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 2003 1.26
159 Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 2006 1.25
160 ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Genet 2005 1.25
161 Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006 1.25
162 Exposing the cancer genome atlas as a SPARQL endpoint. J Biomed Inform 2010 1.25
163 Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012 1.25
164 Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 2006 1.24
165 Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 2007 1.24
166 Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007 1.24
167 Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer 2012 1.23
168 ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003 1.23
169 Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells. Proc Natl Acad Sci U S A 2007 1.22
170 WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 2005 1.22
171 Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J 2007 1.22
172 Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007 1.22
173 Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol 2012 1.21
174 The emerging role of the RAB25 small GTPase in cancer. Traffic 2009 1.21
175 Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther 2010 1.21
176 Stem cell-ness: a "magic marker" for cancer. J Clin Invest 2005 1.20
177 PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014 1.19
178 Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCα invasive signaling axis. Sci Signal 2012 1.19
179 Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J Natl Cancer Inst 2010 1.19
180 Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol 2005 1.18
181 Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. J Med Chem 2003 1.18
182 Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011 1.17
183 Serial dilution curve: a new method for analysis of reverse phase protein array data. Bioinformatics 2009 1.17
184 Bayesian inference of signaling network topology in a cancer cell line. Bioinformatics 2012 1.17
185 Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One 2008 1.17
186 Data integration gets 'Sloppy'. Nat Biotechnol 2006 1.17
187 Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem 2004 1.17
188 Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 2013 1.17
189 EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J 2011 1.17
190 Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res 2006 1.17
191 Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer 2002 1.16
192 DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 2011 1.15
193 Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006 1.15
194 Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 2008 1.15
195 Rab GTPases implicated in inherited and acquired disorders. Semin Cell Dev Biol 2010 1.15
196 PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 2010 1.15
197 A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 2011 1.15
198 Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 2010 1.14
199 Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal 2012 1.14
200 Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 2002 1.14
201 Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2013 1.12
202 Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 2012 1.12
203 Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 2003 1.12
204 Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2009 1.12
205 Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 2015 1.11
206 Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 2003 1.11
207 Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 2006 1.11
208 Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 2006 1.11
209 Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 2008 1.09
210 Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem 2004 1.09
211 Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2004 1.08
212 Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res 2010 1.08
213 Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 2010 1.08
214 AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 2008 1.07
215 LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 2012 1.07
216 Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 2003 1.07
217 Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009 1.06
218 The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol 2006 1.06
219 Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. Cancer Discov 2012 1.06
220 Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One 2012 1.06
221 Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 2014 1.05
222 Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin Cancer Res 2012 1.05
223 Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab 2013 1.04
224 Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 2005 1.04
225 Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol 2011 1.04
226 Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol 2008 1.04
227 Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med 2012 1.03
228 Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2003 1.03
229 Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 2005 1.03
230 Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochim Biophys Acta 2008 1.03
231 A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 2014 1.03
232 Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One 2011 1.02
233 Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity. J Biol Chem 2006 1.01
234 Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther 2012 1.01
235 Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 2014 1.01
236 Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 2012 1.01
237 Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol 2006 1.00
238 CanDrA: cancer-specific driver missense mutation annotation with optimized features. PLoS One 2013 1.00
239 BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol 2013 1.00
240 Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 2012 1.00
241 Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 2003 0.99
242 BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal 2013 0.97
243 Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 2011 0.97
244 Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol Oncol 2013 0.97
245 High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 2012 0.97
246 Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 2013 0.96
247 Structure-activity relationships of fluorinated lysophosphatidic acid analogues. J Med Chem 2005 0.96
248 Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 2012 0.96
249 Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 2009 0.95
250 Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem 2011 0.95
251 Rab25 in cancer: a brief update. Biochem Soc Trans 2012 0.94
252 Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One 2010 0.94
253 Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 2006 0.94
254 Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003 0.93
255 Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. FASEB J 2008 0.93
256 Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 2016 0.93
257 Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Adv Exp Med Biol 2008 0.92
258 Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res 2014 0.92
259 Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. Int J Mol Epidemiol Genet 2010 0.91
260 Proteomic classification of breast cancer. Curr Drug Targets 2012 0.91
261 Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 2012 0.91
262 Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. Mol Oncol 2008 0.90
263 Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists. ChemMedChem 2006 0.90
264 Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A 2008 0.90
265 Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 2009 0.90
266 YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. Stem Cells 2014 0.89
267 Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 2012 0.89
268 Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol 2003 0.89
269 Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res 2014 0.89
270 AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 2010 0.89
271 Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2007 0.89
272 A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res 2005 0.88
273 Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res 2013 0.88
274 Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 2007 0.88
275 A systems approach to analysis of molecular complexity in breast cancer. Clin Cancer Res 2009 0.88
276 Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res 2013 0.88
277 RPPAML/RIMS: a metadata format and an information management system for reverse phase protein arrays. BMC Bioinformatics 2008 0.88
278 AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. EMBO Rep 2012 0.88
279 RET fusion as a novel driver of medullary thyroid carcinoma. J Clin Endocrinol Metab 2014 0.87
280 Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. J Exp Clin Cancer Res 2011 0.87
281 Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res 2005 0.87
282 Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One 2011 0.86
283 ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res 2011 0.86
284 Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 2010 0.86
285 Molecular therapeutics: promise and challenges. Semin Oncol 2004 0.86
286 Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol 2008 0.85
287 Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol 2012 0.85
288 Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. Nat Struct Mol Biol 2011 0.85
289 Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One 2013 0.85
290 Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat 2014 0.84
291 Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med 2014 0.84
292 Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. Bioorg Med Chem Lett 2010 0.84
293 Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun 2010 0.84
294 Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochem Pharmacol 2009 0.84
295 Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. ChemMedChem 2007 0.84
296 Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women. Breast Cancer Res Treat 2013 0.84
297 EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol 2013 0.84
298 Bayesian models based on test statistics for multiple hypothesis testing problems. Bioinformatics 2008 0.84
299 EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol. Mol Oncol 2012 0.84
300 Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet 2006 0.83
301 Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. PLoS One 2012 0.83
302 Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med 2009 0.83
303 Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Res 2014 0.83
304 The impact of tumor heterogeneity on patient treatment decisions. Clin Chem 2012 0.83
305 Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. Mod Pathol 2012 0.83
306 Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Res 2010 0.83
307 Mammalian target of rapamycin. Semin Oncol 2004 0.82
308 Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol 2014 0.82
309 Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. J Biomol Screen 2012 0.82
310 OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer 2014 0.81
311 Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 2003 0.81
312 Ras-superfamily GTP-ases in ovarian cancer. Cancer Treat Res 2009 0.81
313 Bioinformatics and systems biology. Mol Oncol 2012 0.81
314 A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 2013 0.81
315 Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. Cancer Sci 2012 0.81
316 LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J Clin Invest 2014 0.81
317 A time-series DDP for functional proteomics profiles. Biometrics 2012 0.80
318 Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 2002 0.80
319 Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. Cell Cycle 2015 0.79
320 Network inference using steady-state data and Goldbeter-Koshland kinetics. [corrected]. Bioinformatics 2012 0.79
321 Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest 2015 0.78
322 Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. Curr Oncol Rep 2006 0.78
323 Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res 2002 0.78
324 Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 2013 0.78
325 Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy. BMC Med Genomics 2012 0.78
326 Characterization of the role Rab25 in energy metabolism and cancer using extracellular flux analysis and material balance. Methods Mol Biol 2015 0.78
327 Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother 2013 0.78
328 Systematic identification of combinatorial drivers and targets in cancer cell lines. PLoS One 2013 0.78
329 Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 2013 0.77
330 Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 2015 0.76
331 Oxygen sensor boosts growth factor signaling. Nat Med 2009 0.76
332 Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011 0.76
333 Are oncogenes sufficient to cause human cancer? Proc Natl Acad Sci U S A 2010 0.76
334 General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 2003 0.76
335 Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. Breast Cancer Res 2012 0.75
336 Repurposing the Pap smear: one step closer to gynecologic cancer screening. Sci Transl Med 2013 0.75
337 Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 2016 0.75
338 Detection algorithm for the validation of human cell lines. Int J Cancer 2012 0.75
339 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res 2006 0.75
340 Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One 2017 0.75
341 Analysis of molecular aberrations in ovarian cancer allows novel target identification. J Obstet Gynaecol Can 2004 0.75
342 Identifying Abundant Immunotherapy and Other Targets in Solid Tumors: Integrating RNA-seq and Mass Spectrometry Proteomics Data Sets. Cancer J 2017 0.75
343 General keynote: molecular therapeutics and pharmocogenomics. Gynecol Oncol 2003 0.75